Veracyte, INC Form 4 insider transactions

Director Karin Eastham exercised stock options and sold 10,000 shares of Veracyte (VCYT) common stock on April 1, 2024, under a pre-arranged 10b5-1 trading plan.

Rebecca Chambers, CFO of Veracyte, Inc., reports the acquisition of 4,318 shares of common stock and the disposal of 2,189 shares to cover tax obligations.

CEO Marc Stapley reports acquisition of restricted stock units and subsequent disposal of shares to cover tax obligations.

CEO Marc Stapley reports acquiring and disposing of Veracyte common stock, including restricted stock units, according to a Form 4 filing.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., reports the acquisition of common stock and disposal of common stock on March 6, 2024.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the acquisition of restricted stock units.

Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc., reports acquisition and disposal of common stock and restricted stock units.

Rebecca Chambers, CFO of Veracyte, Inc., reported the acquisition of 59,856 shares of common stock and the disposal of 144,573 shares on March 6, 2024.

Phillip G. Febbo, Chief Scientific & Medical Officer of Veracyte, Inc., reports the acquisition of restricted stock units and a disposition of common stock on March 6, 2024.

Annie McGuire, SVP, General Counsel of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to the vesting of Restricted Stock Units.

Jonathan Wygant, VP and Chief Accounting Officer of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

Director Evan Jones exercised stock options and sold 10,000 shares of Veracyte (VCYT) common stock on March 1, 2024.

Rebecca Chambers, CFO of Veracyte, Inc., reports the withholding of common stock to cover tax obligations related to the vesting of Restricted Stock Units.

John Leite, Chief Commercial Officer-CLIA of Veracyte, Inc., reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

CEO Marc Stapley reports the withholding of Veracyte common stock to cover tax obligations related to vesting restricted stock units, along with stock purchases through the employee stock purchase plan.